Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II trial of ZLX-1 for treating stress-related insomnia.

Next Previous
Trial Profile

A Phase II trial of ZLX-1 for treating stress-related insomnia.

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 30 Aug 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ZLX 1 (Primary)
  • Indications Insomnia
  • Focus Therapeutic Use

    • Most Recent Events

    • 25 Aug 2017 According to a Blake Insomnia Therapeutics media release, the company has submitted its clinical trial application (CTA) for Phase II clinical testing to Health Canada.
    • 25 Feb 2017 According to a Blake Insomnia Therapeutics media release, company is planning to submit a New Drug Application in Canada with US in Q2 2017 and International submissions to follow later.
    • 08 Feb 2017 According to Blake Insomnia Therapeutics media release, this trial is planned for Q2 2017, with successful filing and approval, the product is expected to be launched in the US in 2022.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top